US/UK/Canada

Share

Contacts

  • Ulf Hannelius

    CEO


    Box 7349, SE-103 90 Stockholm
    +46 8 661 00 26
    +46 8 661 63 68
    https://www.diamyd.com

    • Links

    Quotes

    The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.
    Ulf Hannelius, CEO
    Our top strategic priority is to prepare for a marketing application for Diamyd®
    Ulf Hannelius, CEO
    Pick a time period -
    Tags ( Active)

    New trial with Diamyd[®] in autoimmune diabetes has started recruiting patients in Norway

    GADinLADA is the first clinical phase II trial with the diabetes vaccine Diamyd[®] adminstered directly into the lymph node in patients with the form of autoimmune diabetes called LADA (Latent Autoimmune Diabetes in Adults).The investigator initiated clinical phase II trial, GADinLADA, is now open for recruitment at the Norwegian University of Science and Technology in Trondheim (NTNU), in cooperation with St. Olav’s University Hospital, Trondheim. The trial will also be conducted in Sweden at the Center for Diabetes, the Academic Specialist Center, an academic specialist unit that is run

    Diamyd Medical and UCLA advance therapeutic development for type 1 diabetes

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today that Diamyd Medical has agreed to further advance its Antigen Based Technology together with researchers at the University of California, Los Angeles (UCLA). Strong synergistic effects have earlier been reported in an animal model receiving GABA in combination with either GAD65 or proinsulin. This new preclinical study will evaluate if GABA in combination with both autoantigens improves efficacy even further. Diamyd Medical licenses exclusive rights from UCLA for the therapeutic use of GABA alone or in combination

    EDCR has started – first patient included in new study combining the diabetes vaccine Diamyd® with etanercept

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today that the first patient has been included in a new study, EDCR, in which the diabetes vaccine Diamyd® will be combined with two other approved agents, the immunosuppressive drug etanercept and vitamin D, with the aim to evaluate the safety of the combination treatment as well as its impact on the immune system in children and adolescents newly diagnosed with type 1 diabetes. With the start of EDCR a total of six clinical studies are now ongoing where alternative approaches with Diamyd® are being tested, either in

    The diabetes vaccine Diamyd® in new study to stop type 1 diabetes in children

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that DiAPREV-IT 2 has started. In this new study, the second of its kind, the diabetes vaccine Diamyd® is tested to prevent or delay the onset of type 1 diabetes in children at very high risk of presenting with the disease.The first participant out of 80 has now been included in DiAPREV-IT 2, a placebo controlled Phase II study where the diabetes vaccine Diamyd® is administered with the aim of preventing or delaying type 1 diabetes. The children participating in the study are seemingly healthy, but have been identified to

    First patient enrolled in new study where the Diamyd® diabetes vaccine is administered directly into lymph nodes - DIAGNODE has started

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that the first patient has been enrolled in the DIAGNODE study. In the study a new way to administer the Diamyd® diabetes vaccine is tested, directly into inguinal lymph nodes.DIAGNODE is the first study of its kind, where a low dose of Diamyd® is administered directly into lymph nodes in combination with treatment with vitamin D. The concept, for which Diamyd Medical has submitted a patent application, can be compared to the development in allergy therapy, where the administration of allergen into lymph nodes has

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media